Cannabis company Curaleaf draws downgrade to hold at Benchmark, while Wedbush sticks to outperform

Benchmark flags cannabis market "uncertainty" while Wedbush sees "good start" to 2023 after Curaleaf beats revenue target, posts narrower-than-expected loss.